ITG's Majestic Market Research Prostate Cancer Study Indicates Amgen's Xgeva Is Poised To Steal Significant Share From Novartis' Zometa; Physicians Still On The Fence About Dendreon's Provenge
Event Pulse: Launches of Xgeva and Provenge includes analysis of a targeted Internet survey of 50 oncologists and 50 urologists, 10 in-depth telephone interviews with pharmacy directors at major managed care organizations, and longitudinal treatment data from a panel of 450 oncologists spanning 2005-2011. Conducted in February to March 2011, the report provides an in-depth look at how the launches of Xgeva and Provenge will impact the treatment paradigm among competing agents in the prostate cancer market. The study also examines the reimbursement climate for existing and anticipated prostate cancer agents.
About Event Pulse
Event Pulse is a syndicated report series that evaluates the impact of market events on physician treatment practices. These reports provide timely insights on how new products, data, and guidelines will affect current treatment algorithms, impact use of available therapies and change market dynamics.
About ITG Majestic Market ResearchITG's Majestic Market Research ("Majestic Market Research") is the primary market research offering of ITG, Inc, (NYSE: ITG), an independent agency brokerage firm founded in 1987. Since 2002, ITG Investment Research has revolutionized the research business with its differentiated research platform based upon leveraging large amounts of statistically relevant, real-time data. While traditional research is frequently based on publicly available data, anecdotal information and channel checks of limited sample sizes, the company leverages its exclusive relationships with industry data providers, unique Web harvesting technology and rigorous primary research capabilities to generate fresh insights from superior analysis of a vast array of data. Majestic Market Research is a specialist in delivering the highest quality, healthcare market intelligence quickly -- combining survey results with empirical data to deliver innovative syndicated and custom reporting. Our cutting-edge market research capabilities enable us to provide clients with the insights and clarity they need to make informed business decisions.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV